Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis

被引：32

作者：

Popat, Sanjay ^{[1
]}

Mellemgaard, Anders ^{[2
]}

Fahrbach, Kyle ^{[3
]}

Martin, Alison ^{[4
]}

Rizzo, Maria ^{[4
]}

Kaiser, Rolf ^{[5
]}

Griebsch, Ingolf ^{[5
]}

Reck, Martin ^{[6
]}

机构：

[1] Royal Marsden Hosp, Dept Med Lung, London SW3 6JJ, England

[2] Herlev Univ Hosp, Dept Oncol, DK-2730 Copenhagen, Denmark

[3] United BioSource Corp, Evidera, Lexington, MA 02420 USA

[4] Evidera, London W6 8DL, England

[5] Boehringer Ingelheim Pharma GmbH & Co KG, D-55216 Ingelheim, Germany

[6] Airway Res Ctr North, LungenClin Grosshansdorf, Dept Thorac Oncol, D-22927 Grosshansdorf, Germany

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 03期

关键词：

adenocarcinoma; chemotherapy; nintedanib; NSCLC; second-line treatment; RANDOMIZED CONTROLLED-TRIAL; ISPOR TASK-FORCE; PHASE-III TRIAL; WILD-TYPE; ERLOTINIB; CHEMOTHERAPY; GEFITINIB; EFFICACY; INHIBITOR; MUTATIONS;

D O I：

10.2217/fon.14.290

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Nintedanib plus docetaxel has proven an overall survival benefit over docetaxel monotherapy in second-line treatment of non-small-cell lung cancer of adenocarcinoma histology in the LUME-Lung 1 pivotal trial. No published trials have previously compared nintedanib plus docetaxel with agents - other than docetaxel - that are approved second-line treatments for non-small-cell lung cancer. Methods: The relative efficacy of nintedanib plus docetaxel versus second-line agents was evaluated by conducting a network meta-analysis of progression-free survival and overall survival. Results: Nine suitable studies were identified. The estimated probability of nintedanib plus docetaxel being the best treatment with regard to overall survival was 70% (versus 16% for pemetrexed, 10% for docetaxel and 3% for erlotinib). Results for progression-free survival were similar. Conclusion: In patients with advanced non-small-cell lung cancer of adenocarcinoma histology, results suggest that nintedanib plus docetaxel offers clinical benefit compared with docetaxel alone, when used as second-line treatment, and suggests that this combination may also add clinical benefit compared with erlotinib in this patient group.

引用

页码：409 / 420

页数：12

共 29 条

[1]

[Anonymous], 2014, NCCN Clinical Practice Guidelines in Oncology: Survivorship

[2] Simultaneous comparison of multiple treatments: combining direct and indirect evidence [J].

Caldwell, DM ;

Ades, AE ;

Higgins, JPT .

BMJ-BRITISH MEDICAL JOURNAL, 2005, 331 (7521) :897-900

[3] Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study [J].

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Miliauskas, Skaidrius ;

Grigorescu, Alexandru Calin ;

Hillenbach, Carina ;

Johannsdottir, Hrefna Kristin ;

Klughammer, Barbara ;

Esteban Gonzalez, Emilio .

LANCET ONCOLOGY, 2012, 13 (03) :300-308

[4] Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial [J].

Douillard, Jean-Yves ;

Shepherd, Frances A. ;

Hirsh, Vera ;

Mok, Tony ;

Socinski, Mark A. ;

Gervais, Radj ;

Liao, Mei-Lin ;

Bischoff, Helge ;

Reck, Martin ;

Sellers, Mark V. ;

Watkins, Claire L. ;

Speake, Georgina ;

Armour, Alison A. ;

Kim, Edward S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (05) :744-752

[5] Non-Small Cell Lung Cancer [J].

Ettinger, David S. ;

Akerley, Wallace ;

Borghaei, Hossein ;

Chang, Andrew C. ;

Cheney, Richard T. ;

Chirieac, Lucian R. ;

D'Amico, Thomas A. ;

Demmy, Todd L. ;

Ganti, Apar Kishor P. ;

Govindan, Ramaswamy ;

Grannis, Frederic W., Jr. ;

Horn, Leora ;

Jahan, Thierry M. ;

Jahanzeb, Mohammad ;

Kessinger, Anne ;

Komaki, Ritsuko ;

Kong, Feng-Ming ;

Kris, Mark G. ;

Krug, Lee M. ;

Lennes, Inga T. ;

Loo, Billy W., Jr. ;

Martins, Renato ;

O'Malley, Janis ;

Osarogiagbon, Raymond U. ;

Otterson, Gregory A. ;

Patel, Jyoti D. ;

Pinder-Schenck, Mary C. ;

Pisters, Katherine M. ;

Reckamp, Karen ;

Riely, Gregory J. ;

Rohren, Eric ;

Swanson, Scott J. ;

Wood, Douglas E. ;

Yang, Stephen C. ;

Hughes, Miranda ;

Gregory, Kristina M. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (10) :1236-1271

[6] Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial [J].

Garassino, Marina Chiara ;

Martelli, Olga ;

Broggini, Massimo ;

Farina, Gabriella ;

Veronese, Silvio ;

Rulli, Eliana ;

Bianchi, Filippo ;

Bettini, Anna ;

Longo, Flavia ;

Moscetti, Luca ;

Tomirotti, Maurizio ;

Marabese, Mirko ;

Ganzinelli, Monica ;

Lauricella, Calogero ;

Labianca, Roberto ;

Floriani, Irene ;

Giaccone, Giuseppe ;

Torri, Valter ;

Scanni, Alberto ;

Marsoni, Silvia .

LANCET ONCOLOGY, 2013, 14 (10) :981-988

[7] Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial [J].

Garon, Edward B. ;

Ciuleanu, Tudor-Eliade ;

Arrieta, Oscar ;

Prabhash, Kumar ;

Syrigos, Konstantinos N. ;

Goksel, Tuncay ;

Park, Keunchil ;

Gorbunova, Vera ;

Dario Kowalyszyn, Ruben ;

Pikiel, Joanna ;

Czyzewicz, Grzegorz ;

Orlov, Sergey V. ;

Lewanski, Conrad R. ;

Thomas, Michael ;

Bidoli, Paolo ;

Dakhil, Shaker ;

Gans, Steven ;

Kim, Joo-Hang ;

Grigorescu, Alexandru ;

Karaseva, Nina ;

Reck, Martin ;

Cappuzzo, Federico ;

Alexandris, Ekaterine ;

Sashegyi, Andreas ;

Yurasov, Sergey ;

Perol, Maurice .

LANCET, 2014, 384 (9944) :665-673

[8] Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J].

Hanna, N ;

Shepherd, FA ;

Fossella, FV ;

Pereira, JR ;

De Marinis, F ;

von Pawel, J ;

Gatzemeier, U ;

Tsao, TCY ;

Pless, M ;

Muller, T ;

Lim, HL ;

Desch, C ;

Szondy, K ;

Gervais, R ;

Shaharyar ;

Manegold, C ;

Paul, S ;

Paoletti, P ;

Einhorn, L ;

Bunn, PA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1589-1597

[9]

Hanna N, 2013, EUR J CANC, V29

[10] BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy [J].

Hilberg, Frank ;

Roth, Gerald J. ;

Krssak, Martin ;

Kautschitsch, Susanna ;

Sommergruber, Wolfgang ;

Tontsch-Grunt, Ulrike ;

Garin-Chesa, Pilar ;

Bader, Gerd ;

Zoephel, Andreas ;

Quant, Jens ;

Heckel, Armin ;

Rettig, Wolfgang J. .

CANCER RESEARCH, 2008, 68 (12) :4774-4782

← 1 2 3 →